Houston, TX, March 26, 2017 --(PR.com
)-- Diabetes is a major lifestyle disorder affecting millions of individuals globally. The disorder is also linked with other complications such as diabetic retinopathy, diabetic foot ulcers, nephropathy and cardiovascular complications among others. Wide spread global prevalence and rising incidence rate has made the antidiabetic drugs market attractive for pharmaceutical drug manufacturers. Introduction of superior products in the recent past and increasing patient compliance are other factors driving the diabetes treatment market. Antidiabetic drugs pipeline, which is rich with potential candidates from leading players such as Pfizer, Novo Nordisk, Sanofi and others, is expected to feed new blockbuster drugs to the market in the near future.
Currently approved drug in the antidiabetic drugs market are categorized under classes including Sulfonylureas (Gliclazide, Glimepiride), Biguanides (Metformine), Thiazolidinediones (Pioglitazone, Rosiglitazone), Dipeptidyl- peptidase-4 (DPP-4) inhibitors (Linagliptine, Sitagliptine), Glucagon-like peptide-1 (GLP-1) agonist (Liraglutide) and Sodium glucose cotransporter-2 inhibitors (SGLT2) (Dapagliflozine, Canaglifozine). Apart from the aforementioned approved drugs, certain drug candidates currently in phase 3 are expected to receive regulatory approval during the forecast period. Pfizer and Merck recently announced positive phase 3 results for ertugliflozin (MK-8835), a sodium glucose co-transporter-2 (SGLT2) inhibitor. Lexicon Pharmaceuticals, Inc. also reported positive topline results in September 2016 for its candidate sotagliflozin. DiaMedica is currently testing potential candidate DM199 for the treatment of diabetic kidney disease. These new candidates would boost the global antidiabetic drugs market.
Request Free Report Sample @ http://www.sa-brc.com/Global-Antidiabetic-Drugs-Market-and-Pipeline-Assessment--Forecast-2017-2021/up88
There exists high demand for diabetes drugs in the Asia Pacific region due to high prevalence. India is considered as a diabetes capital of the world with over 50 million type-2 diabetes patients; while China records 12% of the adult population suffering from diabetes. World Health Organization (WHO) estimates that over 80% of the diabetes mortalities occur in low and middle income countries. This indicates large unmet needs in such countries, where prolonged diabetes therapy is not affordable due to economic crises. According to data published by the World Bank, United States records diabetes prevalence in 10.8% of the population in age group 20 to 79 years, as against 9.3% in India and 9.8% in China. Another data published by the American Diabetes Association estimates total cost of diabetes in the U.S. in 2012 to over US$ 240 billion. The organization also estimates that 1.4 million individuals are diagnosed with diabetes every year in the U.S. alone. Such high prevalence and increasing incidence rate indicate rapid growth potential for the antidiabetic drugs market.
Key players in the antidiabetic drugs market include Pfizer, Inc., Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, AstraZeneca plc, Johnson & Johnson, and others.
Request For TOC@ http://www.sa-brc.com/Global-Antidiabetic-Drugs-Market-and-Pipeline-Assessment--Forecast-2017-2021/upcomingdetail88
Note: This report is currently under research and will be made available to clients on request.